PT-523 for Injection

DRUG3 trials

Sponsors

Spectrum Pharmaceuticals, Inc

Conditions

LeukemiaNeoplasmsNon-Small-Cell Lung Carcinoma

Phase 1

Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness

TerminatedNCT00088023

Spectrum Pharmaceuticals, IncNeoplasms

Start: 2004-03-31End: 2005-12-31Target: 40Updated: 2014-03-31

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

WithdrawnNCT00112060

Spectrum Pharmaceuticals, IncNon-Small-Cell Lung Carcinoma

Start: 2008-04-30End: 2011-09-30Updated: 2014-03-31

A Study to Evaluate PT-523 in Patients With Refractory Leukemia

WithdrawnNCT00129558

Spectrum Pharmaceuticals, IncLeukemia

Start: 2005-07-31End: 2011-09-30Updated: 2013-12-04